3 Cannabis Stocks That Could Benefit the Most from U.S. Legalization

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) and these two other pot stocks will benefit significantly once the U.S. passes legislation that will permit cannabis federally.

| More on:
edit Business accounting concept, Business man using calculator with computer laptop, budget and loan paper in office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Cannabis continues making progress in the U.S. as Illinois recently passed into law a bill that will see it become the 11th state to legalize marijuana for recreational use — and more states that are likely to do the same. Both New York and New Jersey have shown an interest in legalizing cannabis, although the only question is when.

The growth in the U.S. markets is going to create many opportunities for cannabis stocks once marijuana becomes legal federally, and here are three that might be the best buys today:

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is an obvious beneficiary of a growing market since it is, after all, betting on legalization coming sooner rather than later for its deal with Acreage Holdings to go through. Once it is able to be finalized, it will instantaneously make Canopy Growth a major player in the U.S. and worldwide. With more resources and operations to take advantage of, Canopy Growth will be able to rival some of the big multi-state operators in the country.

The company is building on its capacity to produce cannabis, but with the Canadian market offering limited growth, there’s only so much that it can do within its borders in comparison to what’s available in the U.S., one of the key reasons Canopy Growth and other Canadian cannabis companies have looked across the globe for more growth opportunities. Once the U.S. market opens for business, however, Canopy Growth might be in the pole position to take advantage of it.

Charlotte’s Web (TSX:CWEB) already has a big presence in the U.S. in the legal hemp market. Since it is listed on the TSX, it too will have to play by the same rules that Canopy Growth is limited by. Although it could start selling CBD products not derived from hemp in states that have legalized it, that would run contrary to federal laws and would not be in compliance with the TSX.

However, because Charlotte’s Web already is in thousands of retail locations across the U.S., once cannabis is legalized it will have a huge advantage with consumers. having had a big head start in building and developing a brand. When it comes to medical marijuana, trust is important, and the company will have a lot of time to build that with consumers.

When legalization takes place, Charlotte’s Web can piggyback of its existing network of retailers, giving it an easy way to grow its reach by adding new products into circulation.

Trulieve Cannabis Corp (CNSX:TRUL) is also a multi-state operator, but unlike the above two companies, it is listed on the Canadian Securities Exchange (CSE). Thanks to the CSE’s looser requirements, Trulieve can expand to any states that have legalized cannabis. With a strong presence already in Florida, the company has set its sights on Massachusetts, California, and most recently, Connecticut.

Trulieve has the advantage of being able to establish a presence in these locations well before the TSX-listed stocks, giving it an early jump on future competition. Once legalization occurs, we might see Trulieve switch over to the NYSE and TSX at that point in time. For now, however, it can stay on the CSE and continue growing its brand.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »